title: Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
abstract: Reports of osteonecrosis of the jaw (ONJ) in patients receiving long-term bisphosphonate therapy have appeared in the literature since 2003. This condition involves avascular necrotic bone in the area of maxilla or mandibula and there may be a secondary infection. Most cases of ONJ have been reported in cancer patients receiving the intravenous aminobisphosphonates zoledronic acid and pamidronate monthly or q 3 week; of note these are also the two most commonly used agents of this class. Risk factors for ONJ include a history of trauma, dental surgery or dental infection and intravenous bisphosphonate administration; in addition, the extent and duration of exposure to bisphosphonates also seem to correlate with the risk. Although a direct causal relationship with bisphosphonates cannot be assumed, these agents may possibly contribute to the development of ONJ by suppression of bone remodeling in the jaw which leads to increased rates of bone mineralisation and accumulation of microfractures. Clodronate, a non-aminobisphosphonate, appears to have a different mechanism of suppressing bone remodeling compared with aminobisphosphonates, and this may explain why few cases of ONJ have been reported with clodronate despite extensive use over the past 20 years; however, the potential of clodronate to reduce the risk of ONJ while providing equivalent clinical benefit to the aminobisphosphonates needs to be substantiated in controlled clinical trials. Use of bisphosphonate therapy should be carefully planned in patients with metastatic bone disease who have risk factors for ONJ, and appropriate preventive measures taken to avoid the development of this condition.
authors.affiliation: CGG-Klinik GmbH, Institute for Gynecological Oncology, Quadrat P7 16-18, Mannheim 68161, Germany. diel@cgg-mannheim.de
authors.forename: Ingo J
authors.initials: IJ
authors.lastname: Diel
authors.forename: Ignac
authors.initials: I
authors.lastname: Fogelman
authors.forename: Bilal
authors.initials: B
authors.lastname: Al-Nawas
authors.forename: Bodo
authors.initials: B
authors.lastname: Hoffmeister
authors.forename: Cesar
authors.initials: C
authors.lastname: Migliorati
authors.forename: Joseph
authors.initials: J
authors.lastname: Gligorov
authors.forename: Kalervo
authors.initials: K
authors.lastname: Väänänen
authors.forename: Liisa
authors.initials: L
authors.lastname: Pylkkänen
authors.forename: Martin
authors.initials: M
authors.lastname: Pecherstorfer
authors.forename: Matti S
authors.initials: MS
authors.lastname: Aapro
mesh_terms: D004164:Diphosphonates / Q000009:adverse effects* / Q000737:chemistry*; D006801:Humans; D015994:Incidence; D007571:Jaw Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy*; D008954:Models, Biological; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy*; D012307:Risk Factors; D013329:Structure-Activity Relationship
chemical_list: D004164:Diphosphonates